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To gain further information on the possible role of To maximize detection of mutations, SSCP analysis
(Orita et al. 1989) of the PCR products (40–200 ng ofthe PMP70 gene in patients with peroxisomal biogenesis
disorders belonging to complementation group 1, we DNA) was conducted under two conditions, either with
gels containing 7.6% acrylamide, 0.4% bisacrylamide,have investigated, with the approval of The Women’s
and Children’s Hospital Research Ethics Committee, 12 10% (v/v) glycerol, and 1 1 Tris-borate EDTA, which
were run at ambient temperature for 20 h at 21 W,Australian patients for the presence of mutations in the
PMP70 gene. The seven female and ﬁve male patients or with 9.8% acrylamide, 0.2% bisacrylamide, 4%(v/v)
glycerol, and 1 1 Tris-borate EDTA gels, which wereinvestigated in this study all had a clinical phenotype
indicative of a peroxisomal biogenesis disorder. Eight run at 4C for 6 h at 75 W. Prior to electrophoresis, the
samples were mixed with 6 vol of loading dye (96%of the patients showed the more severe phenotype of
Zellweger syndrome, and the remaining four patients formamide, 20 mM EDTA, 0.5 mg bromophenol blue/
ml, 0.5 mg xylene cyanol/ml, and 10 mM NaOH), thenhad the milder, infantile Refsum disease phenotype. In
each case the clinical diagnosis was conﬁrmed biochemi- denatured by boiling for 3 min, and rapidly cooled on
ice. After electrophoresis, the gels were silver stained bycally by methods described elsewhere (Paton et al.
1996). There was no known consanguinity in any of use of the method of Budowle et al. (1991). In addition,
PMP70 products A–D and F–I were digested with thethe families. The patients studied here were assigned to
complementation group 1 by N. Shimozawa, Y. Suzuki, indicated restriction enzyme (table 1), to yield products
close to the optimal size for detection of conformationaland T. Orii, all at The Gifu University School of Medi-
cine, using their catalase immunoﬂuorescence method polymorphisms (Shefﬁeld et al. 1993), and then also
were analyzed on gels. Mobility differences under both(Yajima et al. 1992), and this was conﬁrmed for three
of the patients by use of pristanic acid oxidation to assess SSCP conditions for fragment A, either before or after
restriction-enzyme digestion, indicated the presence ofperoxisomal integrity (Paton et al. 1996). Four of the
patients had both affected and nonaffected sibs, a pat- a polymorphism in this region of the cDNA sequence.
The PCR products were sequenced by use of the dideoxytern consistent with autosomal recessive inheritance,
given that their parents were not affected. chain-termination method (Sanger et al. 1977), with 75
pmol of PCR product and 20 ng of [g-32P] end-labeledTo exclude the possibility of a rearrangement of the
DNA in the gene for PMP70, genomic DNA was ex- primer (table 1) per reaction and 25 ampliﬁcation cycles
(95C for 20 s, 60C for 30 s, and 72C for 1 min). Thistracted from the ﬁbroblasts of all 12 patients, as well as
from controls, by use of DNAzolTM reagent (GIBCO conﬁrmed that the polymorphism corresponded to a
known synonymous (K54K) polymorphism (Ga¨rtner etBRL Life Technologies). The DNA was digested sepa-
rately with EcoRI and HindIII and hybridized with a al. 1992b). Allele frequencies for the polymorphism
were consistent with those published by Ga¨rtner et al.mixed probe after Southern blotting. The probe was
prepared from overlapping PCR products for PMP70 (1992b), and heterozygosity at nucleotide 162 in ﬁve of
the patients provided evidence that both alleles were(corresponding to fragments A/B, C/D, E/F, G/H,
and I/J; table 1) prepared from control cDNA. The transcribed in these individuals.
Apart from the aforementioned polymorphism, noPCR products were randomly labeled with [a-32P]CTP
by use of an Amersham Multiprime DNA labeling kit. clear differences were observed on SSCP gels. Neverthe-
less, some other minor variations were noted, and theseWhen compared with controls, no differences were ob-
served in the restriction-enzyme digest patterns for any were investigated further by sequencing the relevant re-
gions, but no nucleotide differences were found. For allof the 12 patients studied.
RNA of patients was extracted from ﬁbroblast pellets 10 samples (6 patients and 4 controls) sequenced at
nucleotide 33 (numbered from the initiation codon), theby use of the method of Chomczynski and Sacchi (1987),
and cDNA was prepared by use of reverse transcriptase. base differed from that published by Ga¨rtner et al.
(1992a) but agreed with the alternative human PMP70Ten overlapping PCR fragments (A–J; table 1) of the
PMP70 cDNA sequence (Ga¨rtner et al. 1992a) were then sequence published by Kamijo et al. (1992). The amount
of PMP70 cDNA sequenced for nine of the patients isgenerated from the cDNA of the 12 patients, as well as
from that of controls. In every case, PCR products of indicated in table 2. For three patients, almost the entire
cDNA for PMP70 was sequenced, and no mutationsthe correct size were generated, ruling out the possibility
of all but very small insertions or deletions in the coding were identiﬁed. The possibility of an mRNA-negative
allele was excluded in these individuals, since they wereregion of the expressed alleles. Although over- or under-
expression of the PMP70 gene could be deleterious, heterozygous for the polymorphism at nucleotide 162.
Under the conditions used, we believe that SSCP anal-there was no suggestion that this was the case in any of
the patients, with the amount of PCR product generated ysis should have detected most mutations in the PMP70
cDNA sequence. In addition to the polymorphism atfrom the patients’ samples being similar to that in
controls. nucleotide 162 of the PMP70 cDNA sequence, SSCP
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Table 1
Oligonucleotide Primers Used to Generate PCR Products from PMP70 cDNA
Oligonucleotide Sequence Product Size Restriction Single-Stranded Fragment Sizes
Product (5r3) Location (bp) Enzyme (Nucleotides)
GGCGGCCTTCAGCAAGTACTTGAC 3–26 99, 99
A 290 BsuRI
ATGTTCGAGACACCAGCATAACAG 292–269 191, 191
AGGTGTTTTTCTCAAGGCTCATAC 182–204 104, 106
B 296 TaqI
AGTGAGCCTTACTCGGAAGCACAG 477–454 190, 192
TCAACTTCATCGCTGCCATGCCTC 380–403 149, 152
C 333 HinfI
CCAAGTAGGCCATCATGCTCGCTG 712–689 181, 184
ACCAGCTGCTTACACAAGATGTAG 557–580 106, 106
D 335 HincII
TCGGAAGACTGAGTGGACTGTCTG 891–868 229, 229
CGACTTCGAAGACCCATTGGTAAG 736–759
E 263
ACAACTAGGTAACCAACAACAGTG 998–957
TTGTTTCGGTTTTCAATGGGCTTC 922–945 138, 142
F 312 XbaI
GACCATTGTGCGCTCATATTTGCC 1233–1210 170, 174
ATAGTTTTGGCTGGGCGTGAAATG 1120–1143 102, 104
G 309 HinPI
GCCATTTGGACCACAAATTAGAAC 1428–1405 205, 207
TGATCATGTTCCTTTAGCAACGCC 1326–1349 145, 145
H 343 BsuRI
TTCAAGGATATGACCCAACTGGAC 1668–1645 198, 198
GGACGAGAAGATCAGAAAAGGAAG 1582–1605 228, 228
I 291 HincII
AGACACAGTGAAGAGAGTGATGCC 1872–1849 63, 63
GTTAGTGTCGACGTGGAAGGCTAC 1801–1824
J 213
TTCACTGAAGCAGGTATAGTTCTC 2013–1990
analysis has readily detected the presence of mutations negative effect, in which case an individual with a
single mutant PMP70 allele would manifest symptomsin homologous proteins such as those coded by the
of the disorder, and fewer mutant alleles would beALDP gene (Kok et al. 1995) and the CFTR gene (Chil-
expected/found among the relevant patients. Somelo´n et al. 1994; Ravnik-Glavac et al. 1994). Also, the
support for this hypothesis comes from the knowledgepolymorphism at nucleotide position 162 makes it un-
that PMP70 contains only half the necessary domainslikely that all of the patients’ alleles share a common
to form a transporter and that therefore, in order tomutation that we have failed to detect. Indeed, given
function, must form a dimer with a similar ABC trans-that our 12 patients were all unrelated, a number of
porter. Members of the ABC transporter family withdifferent mutations (as many as 24) might be expected.
half the complement of domains are known to formIt has been suggested that some PMP70 mutations
either homo- or heterodimers (Higgins 1992). If a mu-(e.g., the splice-site mutation leading to a 23-bp inser-
tant PMP70 allele produces a stable polypeptide prod-tion [Ga¨rtner et al. 1992a]) could have a dominant-
uct, then it is possible that its incorporation into di-
mers might have a dominant-negative effect on
transporter function. However, as indicated earlier, aTable 2
dominant inheritance pattern is unlikely in four of our
Sequencing of Patients’ cDNA for PMP70 (1,980 Nucleotides, families, unless a gonadal mosaic involving a mutant
Including Stop Condon) allele with a dominant-negative effect were involved.
If PMP70 forms a heterodimer, insufﬁcient functional
NO. (%) OF NUCLEOTIDES SEQUENCED
transporter might also be formed if the individual is
heterozygous for mutations in both components of thePATIENT In Both Directions In at Least One Direction
transporter; and, again, fewer mutant PMP70 alleles
1 355 (17.9) 556 (28.1) would be expected in the patients. Interestingly, two
2 1,580 (79.8) 1,936 (97.8) genes associated with peroxisome-deﬁcient Hansenula
3 354 (17.9) 467 (23.6)
polymorpha mutants have recently been shown to in-4 1,746 (88.2) 1,945 (98.2)
volve both dominant-negative and recessive mutant5 1,475 (74.5) 1,934 (97.7)
6 597 (30.2) 708 (35.8) alleles (Tan et al. 1995). In addition, two Saccharo-
7 911 (46.0) 1,102 (55.7) myces cerevisiae genes have recently been described
8 454 (22.9) 707 (35.7) that code for ABC transporters. Mutants of either
9 149 (7.5) 267 (13.5)
gene are unable to oxidize oleic acid, an entirely per-
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diagnosis of peroxisomal b-oxidation defects. J Clin Invest countries. As a major result, the 15257 mutation was
97:681–688 found in 6 (4%) of 159 families, and in every one of
Ravnik-Glavac M, Glavac D, Dean M (1994) Sensitivity of these instances it was associated with one of the estab-
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tions. Genomics 16:325–332 any of the three established primary mutations. We
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the mutation pattern included at least one primary orpatient with peroxisomal assembly factor-1 (PAF-1) defect.
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Waterham HR, Evers M, et al (1995) Characterization of this latter family. Of the eight families tested in that
peroxisome-deﬁcient mutants of Hansenula polymorpha. paper, the singleton 15257 family showed the highest
Curr Genet 28:248–257 penetrance (56%, all males). Meanwhile, we identiﬁed
Yajima S, Suzuki Y, Shimozawa N, Yamaguchi S, Orii T,
38 further LHON index cases. Our total LHON collec-Fujiki Y, Osumi T, et al (1992) Complementation study of
tive (n Å 55) now consists of 24 carriers of 11778, 5peroxisome-deﬁcient disorders by immunoﬂuorescence
carriers of 3460, and 21 carriers of 14484; the 15257staining and characterization of fused cells. Hum Genet 88:
mutation is found three times associated with np 11778,491–499
six times associated with np 14484, and ﬁve times with-
out any of the established primary mutations. The per-Address for correspondence and reprints: Dr. Barbara Paton, Department of
Chemical Pathology, Women’s and Children’s Hospital, 72 King William Road, centage of LHON patients carrying the 15257 mutation
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Two other groups also reported singleton 15257 LHON
cases (Howell et al. 1993; Brown et al. 1995), and, in
these studies, other pathogenic mtDNA mutations could
be excluded by screening most of the mtDNA coding
Am. J. Hum. Genet. 60:1539–1542, 1997 regions.
The pathogenicity of the 15257 mutation is also dis-
cussed with respect to its haplogroup speciﬁcity. ThisDisease Relevance of the So-Called Secondary Leber
mutation is nearly always associated with the mutationsHereditary Optic Neuropathy Mutations
at nps 4216 and 13708 (Johns and Berman 1991; Brown
To the Editor: et al. 1992). Mackey et al. (1996, p. 484) concluded
that ‘‘the increased frequency of the 15257 mutationIn the August issue of the Journal, Mackey et al. (1996)
addressed the open question of the pathogenic role of among LHON patients can be explained solely in terms
of population history and genetics, rather than as a re-the mtDNA mutation at nucleotide position (np) 15257
in Leber hereditary optic neuropathy (LHON). This was ﬂection of its pathogenic role.’’ In order to look for an
association of certain haplogroups with distinct neuro-done by investigating a total of 159 LHON families
from Australia/New Zealand and from several European degenerative disorders, we currently are investigating
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